Clinical Trials Logo

Myelodysplastic Syndromes clinical trials

View clinical trials related to Myelodysplastic Syndromes.

Filter by:

NCT ID: NCT04620681 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

Start date: January 14, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to determine the safety of an investigational treatment for myelodysplastic syndrome (MDS) after the first therapy (such as azacitidine or decitabine) stops working or after progression of MDS to acute myeloid leukemia (AML). Funding source - FDA OOPD.

NCT ID: NCT04609826 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

DHODH
Start date: November 26, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in combinations.

NCT ID: NCT04603001 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Start date: December 1, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy

NCT ID: NCT04582539 Active, not recruiting - Multiple Myeloma Clinical Trials

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

LIMBER
Start date: August 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

NCT ID: NCT04522895 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Start date: August 27, 2020
Phase: Phase 2
Study type: Interventional

This is a prospective, open label, single arm, multi-centre phase II trial aiming to evaluate the safety and efficacy of Enasidenib (investigational product) as prophylactic consolidation in patients with IDH2-mutated MDS, CMML and AML in remission after allo-SCT.

NCT ID: NCT04478227 Active, not recruiting - Thrombocytopenia Clinical Trials

TPO-Mimetic Use in Children for Hematopoietic Failure

Start date: August 18, 2020
Phase: Early Phase 1
Study type: Interventional

This is an open label, prospective Pilot interventional study will investigate the safety and efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with broad scope of bone marrow failure disorders including acquired and inherited conditions as a first line of therapy along with standard of care.

NCT ID: NCT04477850 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

Start date: November 30, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of luspatercept (ACE-536) for the treatment of anemia due to Revised International Prognostic Scoring System (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) in Chinese and Japanese participants with ring sideroblasts who require Red Blood Cells (RBC) transfusions.

NCT ID: NCT04477291 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Start date: October 6, 2020
Phase: Phase 1
Study type: Interventional

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

NCT ID: NCT04473911 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Haplo Peripheral Blood Sct In GVHD Prevention

Start date: August 14, 2020
Phase: Phase 1
Study type: Interventional

This research study is studying the RGI-2001 for preventing Graft-vs-Host Disease (GVHD) in people with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), chronic myelomonocytic leukemic (CMML), chemosensitive hodgkin lymphoma (HL), or Non-Hodgkin lymphoma (NHL).who will have a blood stem cell transplantation. - GVHD is a condition in which cells from the donor's tissue attack the organs. - RGI-2001 is an investigational treatment

NCT ID: NCT04417517 Active, not recruiting - Clinical trials for Higher Risk Myelodysplastic Syndromes

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

Start date: October 2, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).